Stockscreener 앱 받기
1.48
5.71%
0.08
시간 외 거래:
1.45
-0.03
-2.03%
Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스
Allarity Therapeutics Advances Stenoparib Toward Phase 3 and FDA Approval in Ovarian Cancer with Manufacturing Milestone - Minichart
Stenoparib Phase 3 manufacturing on track as Allarity (NASDAQ: ALLR) preps trials - Stock Titan
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - Investing News Network
Allarity advances stenoparib manufacturing for pivotal trial By Investing.com - Investing.com South Africa
Allarity readies ovarian cancer drug with no more manufacturing cash due - Stock Titan
What Allarity (ALLR) is doing to earn customer loyalty (Institutional Demand) 2026-05-05Hot Market Picks - Newser
[ARS] Allarity Therapeutics, Inc. SEC Filing - Stock Titan
Allarity Therapeutics (NASDAQ: ALLR) details 2026 votes on ELOC, pay and equity plan - Stock Titan
Equity grant gives Allarity Therapeutics (ALLR) officer 133,333 RSUs - Stock Titan
Allarity Therapeutics (ALLR) CFO awarded 150,000 restricted stock units - Stock Titan
USPTO allows Allarity (NASDAQ: ALLR) stenoparib DRP patent with exclusivity to 2039 - Stock Titan
Allarity receives USPTO patent notice for stenoparib diagnostic - Investing.com UK
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Investing News Network
Allarity receives USPTO patent notice for stenoparib diagnostic By Investing.com - Investing.com Australia
Allarity Therapeutics announces that the stenoparib drp® test has received a notice of allowance from the US Patent and Trademark Office - marketscreener.com
SEC Form 424B3 filed by Allarity Therapeutics Inc. - Quantisnow
255,103 Shares Registered for Resale by 3i, LP — Allarity (NASDAQ: ALLR) - Stock Titan
[EFFECT] Allarity Therapeutics, Inc. SEC Filing - Stock Titan
Allarity Therapeutics (NASDAQ: ALLR) updates auditor consent in S-3/A - Stock Titan
ALLR (Allarity Therapeutics Inc.) reports narrower Q3 2025 loss than expected, but shares dip slightly in today’s trading.Earnings Miss - Xã Thanh Hà
Allarity Therapeutics (NASDAQ: ALLR) highlights new stenoparib and DRP® data from AACR 2026 - Stock Titan
Allarity presents cancer drug data at AACR meeting By Investing.com - Investing.com India
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer - Investing News Network
Allarity presents cancer drug data at AACR meeting - Investing.com
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer - ChartMill
Allarity (ALLR) Stock Enterprise Value (Drifts Higher) 2026-04-20Trending Buy Opportunities - Xã Vĩnh Công
Aug Reactions: Will Allarity Therapeutics Inc stock recover after earningsPortfolio Risk Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Earnings Miss: Can Allarity Therapeutics Inc weather a recessionCEO Change & AI Driven Stock Price Forecasts - baoquankhu1.vn
[PRE 14A] Allarity Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
ALLR: Ascendiant Capital Maintains Buy Rating, Raises Price Targ - GuruFocus
Allarity Therapeutics, Inc. (ALLR) stock price, news, quote and history - uk.finance.yahoo.com
Allarity Therapeutics Reports 2025 Financial Results, Advances Stenoparib in Ovarian and Lung Cancer with FDA Fast Track Designation - Minichart
Allarity Therapeutics posts $320k revenue, $11.2M net loss and $14.7M year-end cash (2025) - TradingView — Track All Markets
Allarity Therapeutics (NASDAQ: ALLR) cuts 2025 loss to $11.2M and posts first revenue - Stock Titan
ALLR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ALLR SEC FilingsAllarity 10-K, 10-Q, 8-K Forms - Stock Titan
Allarity Therapeutics, Inc. (ALLR) Stock Price, News, Quote & History - ca.finance.yahoo.com
TON Strategy Company (VERB) Reports FY2025 Earnings - AlphaStreet
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - Investing News Network
Allarity Therapeutics, Inc. (ALLR) Reports FY2025 Earnings - AlphaStreet
Purple Innovation, Inc. (PRPL) Reports Q4 Earnings - AlphaStreet
Allarity Therapeutics reports full year 2025 financial results and corporate progress - marketscreener.com
Market Catalysts: Is Allarity Therapeutics Inc stock forming a cup and handleWeekly Investment Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate Progress - TradingView
Stenoparib push: Allarity Therapeutics (NASDAQ: ALLR) reshapes cancer pipeline - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 27.2% - Defense World
Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025. - marketscreener.com
1.77%
0.25%
자본화:
|
볼륨(24시간):